Oral oxymorphone for pain managementCHAMBERLIN, Kevin W; COTTLE, Mark; NEVILLE, Rebecca et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 7-8, pp 1144-1152, issn 1060-0280, 9 p.Article

The efficacy and safety of oral immediate-release oxymorphone for postsurgical painGIMBEL, Joseph; AHDIEH, Harry.Anesthesia and analgesia. 2004, Vol 99, Num 5, pp 1472-1477, issn 0003-2999, 6 p.Article

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneSAMER, C. F; DAALI, Y; WAGNER, M et al.British journal of pharmacology. 2010, Vol 160, Num 4, pp 907-918, issn 0007-1188, 12 p.Article

RESPIRATORY DEPRESSION FROM ALKALOSIS AND OPIOID INTERACTION IN MANHUDSON HE; HARBER PI; SMITH TC et al.1974; ANESTHESIOLOGY; U.S.A.; DA. 1974; VOL. 40; NO 6; PP. 543-552; BIBL. 12 REF.Article

Assessment of a formulation designed to be crush-resistant in prescription opioid abusersVOSBURG, Suzanne K; JONES, Jermaine D; MANUBAY, Jeanne M et al.Drug and alcohol dependence. 2012, Vol 126, Num 1-2, pp 206-215, issn 0376-8716, 10 p.Article

Nociception increases during opioid infusion in opioid receptor triple knock-out miceJUNI, A; KLEIN, G; PINTAR, J. E et al.Neuroscience. 2007, Vol 147, Num 2, pp 439-444, issn 0306-4522, 6 p.Article

Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomersCARLISS, Richard D. S; KEEFER, James F; PERSCHKE, Scott et al.Pharmacology, biochemistry and behavior. 2009, Vol 92, Num 3, pp 495-502, issn 0091-3057, 8 p.Article

DIASTEREOISOMERIC N-TETRAHYDROFURFURYLNOROXYMORPHONES WITH OPIOID AGONIST-ANTAGONIST PROPERTIES.MERZ H; STOCKHAUS K; WICK H et al.1977; J. MEDICIN. CHEM.; U.S.A.; DA. 1977; VOL. 20; NO 6; PP. 844-846; BIBL. 21 REF.Article

HALOTHANE ANAESTHESIA WITH PREMEDICATION IN DOGSDHILLON KS; PAUL BS.1972; INDIAN J. PHYSIOL. PHARMACOL.; INDIA; DA. 1972; VOL. 16; NO 2; PP. 155-158; BIBL. 12REF.Serial Issue

ORIENTATION OF THE OXYGEN ATOM AT C-6 AS A DETERMINANT OF AGONISTIC ACTIVITY IN THE OXYMORPHONE SERIES.RONAI AZ; FOLDES FF; HAHN EF et al.1977; J. PHARMACOL. EXPER. THERAPEUT.; U.S.A.; DA. 1977; VOL. 200; NO 3; PP. 496-500; BIBL. 23 REF.Article

OPIATE RECEPTOR BINDING OF AGONISTS AND ANTAGONISTS AFFECTED DIFFERENTIALLY BY SODIUM = LA FIXATION DES AGONISTES ET DES ANTAGONISTES AU RECEPTEUR DES OPIACES, AFFECTEE DIFFERENTIELLEMENT PAR LE SODIUMPERT CB; SNYDER SH.1974; MOLEC. PHARMACOL.; U.S.A.; DA. 1974; VOL. 10; NO 6; PP. 868-879; BIBL. 35REF.Article

INCREASED BIOLOGICAL ACTIVITY OF DIMERS OF OXYMORPHONE AND ENKEPHALIN: POSSIBLE ROLE OF RECEPTOR CROSSLINKINGHAZUM E; KWEN JEN CHANG; LEIGHTON HJ et al.1982; BIOCHEM. BIOPHYS. RES. COMMUN.; ISSN 0006-291X; USA; DA. 1982; VOL. 104; NO 1; PP. 347-353; BIBL. 24 REF.Article

THE MODE OF ACTION OF PROMETHAZINE IN POTENTIATING NARCOTIC DRUGSKEERI SZANTO M.1974; BRIT. J. ANAESTH.; G.B.; DA. 1974; VOL. 46; NO 12; PP. 918-924; BIBL. 24REF.Article

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetySAMER, C. F; DAALI, Y; WAGNER, M et al.British journal of pharmacology. 2010, Vol 160, Num 4, pp 919-930, issn 0007-1188, 12 p.Article

Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery : A randomized, double-blind, active-and placebo-controlled, parallel-group trialAQUA, Keith; GIMBEL, Joseph S; SINGLA, Neil et al.Clinical therapeutics. 2007, Vol 29, Num 6, pp 1000-1012, issn 0149-2918, 13 p.Article

COMBINATION OF DELTA 9-TETRAHYDROCANNABINOL WITH OXYMORPHONE OR PENTOBARBITAL: EFFECTS ON VENTILATORY CONTROL AND CARDIOVASCULAR DYNAMICS = ASSOCIATION DU DELTA 9-TETRAHYDROCANNABINOL A L'OXYMORPHONE OU AU PENTOBARBITAL. EFFETS SUR LE CONTROLE DE LA VENTILATION ET LA DYNAMIQUE CARDIOVASCULAIREJOHNSTONE RE; LIEF PL; KULP RA et al.1975; ANESTHESIOLOGY; U.S.A.; DA. 1975; VOL. 42; NO 6; PP. 674-684; BIBL. 16REF.Article

Opioid agonists and antagonists. 6,6-Hydrazi and 6-oximino derivatives of 14-hydroxydihydromorphinonesKO, R. P; GUPTE, S. M; NELSON, W. L et al.Journal of medicinal chemistry (Print). 1984, Vol 27, Num 12, pp 1727-1729, issn 0022-2623Article

AN EFFICIENT SYNTHESIS OF N-CYCLOBUTYLMETHYLNOROXYMORPHONE FROM THEBAINE.OLOFSON RA; PEPE JP.1977; TETRAHEDRON LETTERS; G.B.; DA. 1977; NO 18; PP. 1575-1578; BIBL. 14 REF.Article

Pharmacokinetics and pharmacodynamics of controlled-release opioidsKAIKO, R. F.Acta anaesthesiologica scandinavica. 1997, Vol 41, Num 1, pp 166-174, issn 0001-5172, 2Conference Paper

Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysisLEE, M. A; LENG, M. E. F; COOPER, R. M et al.Palliative medicine. 2005, Vol 19, Num 3, pp 259-260, issn 0269-2163, 2 p.Article

Distinction among eight opiate drugs in urine by gas chromatography-mass spectrometryNOWATZKE, W; JIANBO ZENG; SAUNDERS, A et al.Journal of pharmaceutical and biomedical analysis. 1999, Vol 20, Num 5, pp 815-828, issn 0731-7085Article

Oxymorphone par voie orale = Oral oxymorphoneThe Medical letter on drugs and therapeutics (Edition française). 2007, Vol 29, Num 3, pp 11-12, issn 0253-8512, 2 p.Article

The Pain Quality Response Profile of Oxymorphone Extended Release in the Treatment of Low Back PainGOULD, Errol M; JENSEN, Mark P; VICTOR, Timothy W et al.The Clinical journal of pain. 2009, Vol 25, Num 2, pp 116-122, issn 0749-8047, 7 p.Article

Oxymorphone Extended Release for the Treatment of Chronic Low Back Pain : A Retrospective Pooled Analysis of Enriched-Enrollment Clinical Trial Data Stratified According to Age, Sex, and Prior Opioid UsePENISTON, John H; GOULD, Errol.Clinical therapeutics. 2009, Vol 31, Num 2, pp 347-359, issn 0149-2918, 13 p.Article

Page / 4